drugset / Trial / NCT04390295
Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to obtain information on efficacy and safety of SHR3824 with metformin over 24 weeks and 52 weeks in metformin monotherapy poorly glycemic controlled chinese Type 2 Diabetes. Efficacy and safety will be evaluated by comparing the effect of SHR3824 with metformin to placebo with metformin when given in oral doses.
Timeline
- Start
- 2017-11-02
- Primary completion
- 2020-05
- Completion
- 2020-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Henagliflozin | Small molecule | 5 mg | Oral |
| Subject | Henagliflozin | Small molecule | 10 mg | Oral |
| Background | Metformin | Small molecule | — | Oral |